A Real-World Study of Recombinant Human Growth Hormone

OBJECTIVE

The research aimed to evaluate the efficacy of recombinant human growth hormone (rhGH) in treating idiopathic short stature (ISS) and growth hormone deficiency (GHD) in children and also to explore the related factors affecting treatment efficacy.

METHODS

This research is on a real-world study where 79 patients with ISS and 95 patients with GHD (both groups pre-puberty) were treated with rhGH for more than one year from January 2010 to September 2019. The growth indexes, such as chronological age (CA), bone age (BA), height standard deviation score (HtSDS), insulin-like growth factor-1 (IGF-1) SDS, and body mass index were recorded and compared between the two groups before and after treatment to check the treatment efficacy and the influencing factors of clinical efficacy using a multivariate regression model.

RESULTS

The initial dose of rhGH in the GHD group was significantly lower than in the ISS group (P < 0.001). Following rhGH treatment, the differences in CA, BA, BA/CA ratio, and IGF-1 SDS measured at 6, 12, 18, and 24 months between the ISS and GHD groups were not statistically significant, while the difference in HtSDS measured at 6 months was statistically significant. 

CONCLUSION

Recombinant human growth hormone treatment can significantly improve the height of patients with ISS and GHD and no significant difference in growth rate between the patients were found at relatively high doses. The common factor affecting the treatment efficacy was the age at the start of treatment. Moreover, a clinical phenomenon in thyroid function is observed in the monitored data during treatment.
 

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors